#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary biliary cholangitis Synovitis Hereditary motor and sensory neuropathy Renal cell carcinoma C3 glomerulopathy VEXAS syndrome Hyperchylomicronaemia Rett syndrome Alexander disease Blood iron increased Indolent systemic mastocytosis Raynaud's phenomenon Primitive neuroectodermal tumour Paroxysmal nocturnal haemoglobinuria Small intestine leiomyosarcoma More trials…

    Learn about Rare Diseases

    Primary hyperoxaluria – Trials in Disease Marfan’s syndrome Alport’s syndrome – Basic Information Congenital generalised lipodystrophy – Trials in Disease Pemphigoid – Diagnostics Systemic mastocytosis – Life with Disease Carcinoid syndrome – Diagnostics Andersen-Tawil syndrome – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Antithrombin III deficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tocotrienol Chloride Ion Brimonidine Tartrate INSULIN DETEMIR Exagamglogene Autotemcel Nesolicaftor Fentanyl HLX43 Zanamivir Dextromethorphan Hydrobromide CLESROVIMAB Poltreg-T1D Glutathione Fluticasone Furoate Efzofitimod ISPAGHULA HUSK Oxcarbazepine Cabazitaxel Biotin Niraparib More therapies…

    Learn about Your Condition

    Vulvovaginal pruritus Burning mouth syndrome Nephrolithiasis Gouty arthritis Vulval cancer recurrent Retroperitoneal fibrosis Nasopharyngeal cancer Pulmonary fibrosis Epileptic encephalopathy Persistent depressive disorder Hyperthyroidism Habitual abortion Bone hypertrophy Eosinophilic gastritis BRAF gene mutation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer female

  • Study of personalized tamoxifen dosing (10mg, 20mg, or 40mg daily) compared to standard dose (20mg) in women with breast cancer to improve treatment continuation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Tamoxifen
    Sweden

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    • Breast cancer metastatic
    • Ovarian cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Eribulin Mesylate
    • Doxorubicin Hydrochloride, Liposomal
    Portugal

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    Germany

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Biliary cancer metastatic
    • Breast cancer recurrent
    • Breast cancer stage IV
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!